Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Briacell Therapeutics Corp

BCTX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$3.05

▼ -7.85%

Market Cap $26.74M · Vol 24.40K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$26.74M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

24.69

Momentum

Beta

1.25

vs Market

52W High

$12.95

76.45% below

52W Low

$2.61

16.86% above

Volume

24.40K

Avg 20.45K

P/B

0.77

Price-to-book

ROE

N/A

Return on equity

Free Float

99.86%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Briacell Therapeutics Corp (BCTX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BCTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.21%

-28.74%

-15.98%

-27.03%

YTD

-57.10%

-73.15%

-99.51%

-99.74%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-26,556,140.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-192.98% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.77
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	8.70M

Technical Indicators

50-Day SMA	$3.77
200-Day SMA	$3.81
RSI (14)	24.69
Beta	1.25
52-Week High	$12.95
52-Week Low	$2.61

Volume Today	24.40K
Avg Daily Volume (30D)	20.45K
Relative Volume	1.19x
Volatility (10D)	60.63
Volatility (30D)	55.32
Free Float	99.86%

Analyst Consensus

N/A

Current Price $3.05

Mean Target N/A

52W Low$2.61 52W High$12.95

Current

Target

$2.61 $12.95

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SMHR46

ISINCA1079303071

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.